Glydo Jelly
NDC Package 25021-673-77
Package Information
Glydo (lidocaine hydrochloride) jellies is gLYDO (lidocaine HCl jelly) 2% is an amide local anesthetic indicated: for prevention and control of pain in procedures involving the male and female urethra for topical treatment of painful urethritis as an anesthetic lubricant for oral and nasal endotracheal intubation. This formulation utilizes a jelly delivery system. Marketed by Sagent Pharmaceuticals, this product is identified by NDC 25021-673 and is authorized under FDA application ANDA201094.
Identification & Billing
- RxCUI: 1011852 - lidocaine HCl 2 % Topical Gel
- RxCUI: 1011852 - lidocaine hydrochloride 0.02 MG/MG Topical Gel
- RxCUI: 1011852 - lidocaine hydrochloride 2 % Topical Jelly
- RxCUI: 1549447 - Glydo 2 % Topical Jelly
- RxCUI: 1549447 - lidocaine hydrochloride 0.02 MG/MG Topical Gel [Glydo]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 25021 - Sagent Pharmaceuticals
- 25021-673 - Glydo
- 25021-673-77 - 10 SYRINGE in 1 CARTON / 11 mL in 1 SYRINGE
- 25021-673 - Glydo
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (25021-673). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 25021-673-77 identifies a specific commercial package of 10 syringe in 1 carton / 11 ml in 1 syringe of Glydo, a human prescription drug labeled by Sagent Pharmaceuticals. This jelly is formulated for topical use and contains lidocaine hydrochloride anhydrous as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sagent Pharmaceuticals on September 15, 2014. The current certification is valid through December 31, 2027.
How is this Sagent Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 25021067377. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 110 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.